Skip to main content
Top
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Prevalence and associated risk factors for Kaposi’s sarcoma among HIV-positive patients in a referral hospital in Northern Tanzania: a retrospective hospital-based study

Authors: George P. Semango, Renard M. Charles, Consolata I. Swai, Alex Mremi, Patrick Amsi, Tolbert Sonda, Elichilia R. Shao, Daudi R. Mavura, Leo A. B. Joosten, Elingarami Sauli, Mramba Nyindo

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Kaposi’s sarcoma (KS) is a multifocal angioproliferative tumor involving blood and lymphatic vessels, caused by Human Herpes Virus-8 (HHV-8). KS is an important AIDS-defining tumor with high prevalence in Sub-Saharan Africa, including Tanzania which has high HIV and HHV-8 sero-prevalence. It is critically important to monitor the prevalence of AIDS-defining tumors, such as KS, in the age of HIV/AIDS. We studied the prevalence of KS and associated risk factors among HIV-positive patients at Kilimanjaro Christian Medical Centre (KCMC), a referral hospital in northern Tanzania, over the period from January 2012 to December 2015.

Methods

This was a retrospective hospital-based cross-sectional study to determine the prevalence of KS among HIV/AIDS patients between 2012 and 2015. The study included 1100 HIV patients’ data which were collected at the Infectious Disease Clinic (IDC) from patients’ files. Stata version 13 (StataCorp LP, Texas 77,845 USA) was used for all statistical analyses. The prevalence of KS was calculated across levels of a number of categorical variables. Logistic regression was performed to determine relative risk of KS for all characteristics. We included all variables with p-values ≤10% in the multivariate analysis, including ART use, as this is considered to have an influence on KS. In the multivariate analysis, statistical significance was established based on a two-tailed p-value ≤5%. All patients’ notes were kept confidential as per the Helsinki declaration.

Results

Our results revealed a 4.6% prevalence of KS at KCMC hospital, between January 2012 and December 2015, 51(4.6%) patients were diagnosed with KS out of 1100 HIV-positive patients. The study further revealed that KS in HIV patients was most associated with low CD4 cell count (less than or equal to 200 cells/μl). Moreover, women were more likely than men to diagnosed with KS, with higher odds significantly associated with KS (OR 0.42, p < 0.009). Increased age, above 35 years, among the HIV seropositive patients was significantly associated with KS (OR 25.67, p < 0.007). HIV patients who were none smokers were more likely to suffer from KS compared to HIV smokers (OR 0.41, p < 0.010).

Conclusion

KS remains a common malignant vascular tumor commonly associated with HIV/AIDS in Tanzania. Our study highlights the need for continued efforts to combat HIV, as well as associated diseases such as KS. Continued availability of ART (Anti-Retroviral Therapy) to HIV/AIDS patients, and test reagents for CD4 cell count and viral load determination are important measures to alleviate the suffering of these patients. Furthermore, studies to gather more evidence on ART resistance are highly needed to guide treatment choices.
Literature
1.
go back to reference Sternbach G, Varon J. Moritz Kaposi: idiopathic pigmented sarcoma of the skin. J Emerg Med. 1995;13(5):671–4.CrossRef Sternbach G, Varon J. Moritz Kaposi: idiopathic pigmented sarcoma of the skin. J Emerg Med. 1995;13(5):671–4.CrossRef
2.
go back to reference Wen KW, Damania B. Kaposi sarcoma-associated herpesvirus (KSHV): Molecular biology and oncogenesis. Cancer Letters. 2010;Vol. 289:140–50.CrossRef Wen KW, Damania B. Kaposi sarcoma-associated herpesvirus (KSHV): Molecular biology and oncogenesis. Cancer Letters. 2010;Vol. 289:140–50.CrossRef
3.
go back to reference Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science (New York, NY). 1994;266(5192):1865–9.CrossRef Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science (New York, NY). 1994;266(5192):1865–9.CrossRef
4.
go back to reference Sarid R, Calabrò ML. Kaposi’s sarcoma-associated herpesvirus: epidemiology, biological characteristics and pathogenesis. In: Kaslow RA, Stanberry LR, Le Duc JW, editors. Viral infections of humans: epidemiology and control. Boston, MA: Springer US; 2014. p. 897–931. Sarid R, Calabrò ML. Kaposi’s sarcoma-associated herpesvirus: epidemiology, biological characteristics and pathogenesis. In: Kaslow RA, Stanberry LR, Le Duc JW, editors. Viral infections of humans: epidemiology and control. Boston, MA: Springer US; 2014. p. 897–931.
5.
go back to reference Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136(5):E359–86.CrossRef Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136(5):E359–86.CrossRef
6.
go back to reference Ferlay J, Shin H-R, Bray F, Foreman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Vol. 2008, International Agency for Research on Cancer. 2010. p. 1–5. Ferlay J, Shin H-R, Bray F, Foreman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Vol. 2008, International Agency for Research on Cancer. 2010. p. 1–5.
7.
go back to reference Uldrick TS, Whitby D. Update on KSHV epidemiology, Kaposi sarcoma pathogenesis, and treatment of Kaposi sarcoma. Cancer Lett. 2017 Jul 15;305(2):150–62.CrossRef Uldrick TS, Whitby D. Update on KSHV epidemiology, Kaposi sarcoma pathogenesis, and treatment of Kaposi sarcoma. Cancer Lett. 2017 Jul 15;305(2):150–62.CrossRef
9.
go back to reference Koski L, Ngoma T, Mwaiselage J, Le L, Soliman AS. Changes in the pattern of Kaposi’s sarcoma at ocean road Cancer Institute in Tanzania (2006-2011). Int J STD AIDS. 2015;26(7):470–8.CrossRef Koski L, Ngoma T, Mwaiselage J, Le L, Soliman AS. Changes in the pattern of Kaposi’s sarcoma at ocean road Cancer Institute in Tanzania (2006-2011). Int J STD AIDS. 2015;26(7):470–8.CrossRef
10.
go back to reference Mavura DR, Masenga EJ, Minja E, Grossmann H, Crump JA, Bartlett JA. Initiation of antiretroviral therapy in HIV-infected adults with skin complaints in northern Tanzania. Int J Dermatol. 2015;54(1):68–73.CrossRef Mavura DR, Masenga EJ, Minja E, Grossmann H, Crump JA, Bartlett JA. Initiation of antiretroviral therapy in HIV-infected adults with skin complaints in northern Tanzania. Int J Dermatol. 2015;54(1):68–73.CrossRef
11.
go back to reference Gnann JW Jr, Pellett PE, Jaffe HW. Human herpesvirus 8 and Kaposi’s sarcoma in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000;30(Suppl 1):S72–6.CrossRef Gnann JW Jr, Pellett PE, Jaffe HW. Human herpesvirus 8 and Kaposi’s sarcoma in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000;30(Suppl 1):S72–6.CrossRef
12.
go back to reference Martró E, Esteve A, Schulz TF, Sheldon J, Gambús G, Muñoz R, et al. Risk factors for human herpesvirus 8 infection and AIDS-associated Kaposi’s sarcoma among men who have sex with men in a European multicentre study. Int J Cancer. 2007;120(5):1129–35.CrossRef Martró E, Esteve A, Schulz TF, Sheldon J, Gambús G, Muñoz R, et al. Risk factors for human herpesvirus 8 infection and AIDS-associated Kaposi’s sarcoma among men who have sex with men in a European multicentre study. Int J Cancer. 2007;120(5):1129–35.CrossRef
13.
go back to reference Munawwar A, Sharma SK, Gupta S, Singh S. Seroprevalence and determinants of Kaposi sarcoma-associated human herpesvirus 8 in Indian HIV-infected males. AIDS Res Hum Retrovir. 2014;30(12):1192–6.CrossRef Munawwar A, Sharma SK, Gupta S, Singh S. Seroprevalence and determinants of Kaposi sarcoma-associated human herpesvirus 8 in Indian HIV-infected males. AIDS Res Hum Retrovir. 2014;30(12):1192–6.CrossRef
14.
go back to reference Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: A systematic review and meta-regression analysis. The Lancet Infectious Diseases. 2017;(17):30702–8. Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: A systematic review and meta-regression analysis. The Lancet Infectious Diseases. 2017;(17):30702–8.
16.
go back to reference Kagu MB, Nggada HA, Garandawa HI, Askira BH, Durosinmi MA. AIDS-associated Kaposi’s sarcoma in northeastern Nigeria. Singap Med J. 2006 Dec;47(12):1069–74. Kagu MB, Nggada HA, Garandawa HI, Askira BH, Durosinmi MA. AIDS-associated Kaposi’s sarcoma in northeastern Nigeria. Singap Med J. 2006 Dec;47(12):1069–74.
17.
go back to reference Yerly S, Calmy A. Time to overcome pretreatment HIV drug resistance. Lancet Infect Dis. 2017;18(3):239–40.CrossRef Yerly S, Calmy A. Time to overcome pretreatment HIV drug resistance. Lancet Infect Dis. 2017;18(3):239–40.CrossRef
18.
go back to reference Hawkins C, Ulenga N, Liu E, Aboud S, Mugusi F, Chalamilla G, et al. HIV virological failure and drug resistance in a cohort of Tanzanian HIV-infected adults. J Antimicrob Chemother. 2016;71(7):1966–74.CrossRef Hawkins C, Ulenga N, Liu E, Aboud S, Mugusi F, Chalamilla G, et al. HIV virological failure and drug resistance in a cohort of Tanzanian HIV-infected adults. J Antimicrob Chemother. 2016;71(7):1966–74.CrossRef
19.
go back to reference Muri L, Gamell A, Ntamatungiro AJ, Glass TR, Luwanda LB, Battegay M, et al. Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern. AIDS (London, England). 2017;31(1):61–70.CrossRef Muri L, Gamell A, Ntamatungiro AJ, Glass TR, Luwanda LB, Battegay M, et al. Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern. AIDS (London, England). 2017;31(1):61–70.CrossRef
20.
go back to reference Kagu MB, Nggada HA, Garandawa HI, Askira BH, Durosinmi MA. AIDS-associated Kaposi’s sarcoma in northeastern Nigeria. Singap Med J. 2006;47(12):1069–74. Kagu MB, Nggada HA, Garandawa HI, Askira BH, Durosinmi MA. AIDS-associated Kaposi’s sarcoma in northeastern Nigeria. Singap Med J. 2006;47(12):1069–74.
21.
go back to reference Stolka K, Ndom P, Hemingway-Foday J, Iriondo-Perez J, Miley W, Labo N, et al. Risk factors for Kaposi’s sarcoma among HIV-positive individuals in a case control study in Cameroon. Cancer Epidemiol. 2014;38(2):137–43.CrossRef Stolka K, Ndom P, Hemingway-Foday J, Iriondo-Perez J, Miley W, Labo N, et al. Risk factors for Kaposi’s sarcoma among HIV-positive individuals in a case control study in Cameroon. Cancer Epidemiol. 2014;38(2):137–43.CrossRef
Metadata
Title
Prevalence and associated risk factors for Kaposi’s sarcoma among HIV-positive patients in a referral hospital in Northern Tanzania: a retrospective hospital-based study
Authors
George P. Semango
Renard M. Charles
Consolata I. Swai
Alex Mremi
Patrick Amsi
Tolbert Sonda
Elichilia R. Shao
Daudi R. Mavura
Leo A. B. Joosten
Elingarami Sauli
Mramba Nyindo
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-5155-2

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine